194

Mastopatiya – ayollarning eng keng tarqalgan kasalligi bo’lib, mammologiyadagi kasalliklar oqimining 90% ini tashkil etadi. Fibroz kistoz
mastopatiya etiologiyasi oxirigacha aniqlanmagan bo’lib, lekin ko’p o’rganilgan xavf omillariga endokrin buzilishlar, xususan insulinorezistentlik
va qalqonsimon bez kasalliklari kiradi.
Maqsad. FKM bemorlardagi insulinorezistentlik uchrashi va mastopatiyaning klinik kechishiga metformin tasirini o’rganish.
Tadqiqot manbasi va usullari. Tadqiqot manbasi sifatida Toshkent tibbiyot akademiyasi Urganch filiali bazasida fibroz kistoz mastopatiya tashxisi
asosida davolangan 71 ta fertil (18 - 49) yoshdagi ayollar olindi. Bemorlarning o’rtacha yoshi 34,2±0,4 yoshni tashkil etdi. Bemorlarda tana vazni
indeksi o’rtacha 31,4 ±2,54 kg/m2 ni, НOMA indeksi 3,2 ± 0,25 tashkil qildi.
Barcha ayollarda qalqonsimon bezi 7,5 mGts chastotali MINDRAY DC 60 (Yaponiya) ultratovush apparati yordamida sut bezi va qalqonsimon
bez ultratovush tekshiruvi (UTT) o’tkazildi.
Xulosa. Insulinorezistentlikning kamayishi va mastopatiya klinik kechishi orasida kuchli ishonchli bog’liqlik mavjud (р≤0,001).
Insulinorezistenlik bilan kechuvchi mastopatiyasi bor ayollarda metformin qabul qilish va UTT xulosasi BIRADS toifasining kamayishi orasida
ishonchli bog’liqlik mavjud (р≤0,05

  • Ўқишлар сони 194
  • Нашр санаси 15-03-2022
  • Мақола тилиO'zbek
  • Саҳифалар сони36-39
Ўзбек

Mastopatiya – ayollarning eng keng tarqalgan kasalligi bo’lib, mammologiyadagi kasalliklar oqimining 90% ini tashkil etadi. Fibroz kistoz
mastopatiya etiologiyasi oxirigacha aniqlanmagan bo’lib, lekin ko’p o’rganilgan xavf omillariga endokrin buzilishlar, xususan insulinorezistentlik
va qalqonsimon bez kasalliklari kiradi.
Maqsad. FKM bemorlardagi insulinorezistentlik uchrashi va mastopatiyaning klinik kechishiga metformin tasirini o’rganish.
Tadqiqot manbasi va usullari. Tadqiqot manbasi sifatida Toshkent tibbiyot akademiyasi Urganch filiali bazasida fibroz kistoz mastopatiya tashxisi
asosida davolangan 71 ta fertil (18 - 49) yoshdagi ayollar olindi. Bemorlarning o’rtacha yoshi 34,2±0,4 yoshni tashkil etdi. Bemorlarda tana vazni
indeksi o’rtacha 31,4 ±2,54 kg/m2 ni, НOMA indeksi 3,2 ± 0,25 tashkil qildi.
Barcha ayollarda qalqonsimon bezi 7,5 mGts chastotali MINDRAY DC 60 (Yaponiya) ultratovush apparati yordamida sut bezi va qalqonsimon
bez ultratovush tekshiruvi (UTT) o’tkazildi.
Xulosa. Insulinorezistentlikning kamayishi va mastopatiya klinik kechishi orasida kuchli ishonchli bog’liqlik mavjud (р≤0,001).
Insulinorezistenlik bilan kechuvchi mastopatiyasi bor ayollarda metformin qabul qilish va UTT xulosasi BIRADS toifasining kamayishi orasida
ishonchli bog’liqlik mavjud (р≤0,05

№ Ҳавола номи
1 1. Sadaf Alipour, Hadith Rastad Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical tria. DARU Journal of Pharmaceutical Sciences (2021) 29:389–396. 2. Sadaf Alipour, Mahboubeh Abedi. Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial BMC Endocrine Disorders (2021) 21:169 https://doi.org/10.1186/s12902-021-00824-4. 3. Кац И.П., Павлова Е.А., Ордиянц И.М. Роль генетических факторов и иммунных нарушений в развитии доброкачественных заболеваний молочных желез //материалы II Междисциплинарного форума «Медицина молочной железы». М.: Медиабюро Статус презенс, 2012. С. 27–31. 4. Figueroa JD, et al. Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case-control study. Breast Cancer Research & Treatment 2016;159(1):163-172. 5. Мусина Е.В., Коган И.Ю. Возможности применения бигуанидов при фиброзно-кистозной болезни у женщин репродуктивного возраста // Журнал акушерства и женских болезней. - 2019. - Т. 68. - № 3. - С. 35 - 40. 6. Silvera SAN, Rohan TE. Benign proliferative epithelial disorders of the breast: a review of the epidemiologic evidence. Breast Cancer Research and Treatment. 2007;110(3):397 - 409. 7. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103-1123. 8. Gonzalez - Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res. 2010;16(6):1695-1700. 9. Boyd DB. Insulin and Cancer. Integr Cancer Ther. 2016;2(4): 315-329. 10. Tarique M. A Prospective Study on Prevalence of Hyperprolactinemia & Hypothyroidism in Benign Breast Diseases. Int Arch BioMed Clin Res. 2019;5(1):18 – 19. 11. Gunter MJ, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009;101:48– 60. Abstract/FREE Full TextGoogle Scholar. 12. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579- 591. 13. Catsburg C., Gunter M.J., Chen C. et al. Insulin, estrogen, inflammatory markers, and risk of benign proliferative breast disease. Cancer Res 2014;74(12):3248—58. 14. Chelsea Catsburg, Marc J. Gunter, et al. Insulin, Estrogen, Inflammatory Markers, and Risk of Benign Proliferative Breast Disease Cancer Res; 74(12) June 15, 2014 DOI: 10.1158/0008-5472.CAN-13-3514. 15. Heckman - Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia. 2017;60(9):1639-1647. 16. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48(3):R31- 43. 17. Heckman - Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia. 2017;60(9):1639-1647. 18. Tu C, Ren X, He J, Zhang C, Chen R, Wang W, Li Z. The Value of LncRNA BCAR4 as a Prognostic Biomarker on Clinical Outcomes in Human Cancers. J Cancer. 2019;10(24):5992-6002. [PMC free article] [PubMed]. 19. Sonia Del Barco Metformin: Multi-faceted protection against cancer Oncotarget 2011; 2: 896 – 917.
Кутилмоқда